Hemostatic effects of 1 mg daily warfarin on post CABG patients

Journal of Thrombosis and Thrombolysis

Volumn 7, Issue 3, 1999, Pages 313-318

  Walenga, Jeanine M ^a   Hoppensteadt, Debra ^a   Pifarré, Roque ^a   Cressman, Michael D ^b,f   Hunninghake, Donald B ^c   Fox, Norma Lynn ^d,g   Terrin, Michael L ^d   Probstfield, Jeffrey L ^e,h  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d MARYLAND MEDICAL RESEARCH INSTITUTE   (United States)

^e NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^f UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^g GENENTECH INC   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

Author keywords

CABG; Coronary bypass graft; Restenosis; Thrombosis; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 7; FIBRINOGEN; PLASMINOGEN ACTIVATOR; PROTHROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR; WARFARIN;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; FEMALE; HEMOSTASIS; HUMAN; HUMAN CELL; INTERNATIONAL STANDARD UNIT; MALE; MULTICENTER STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RESTENOSIS; REVASCULARIZATION; THROMBOSIS;

AGED; ANTICOAGULANTS; ANTIGENS; CORONARY ARTERY BYPASS; FACTOR VII; FEMALE; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POSTOPERATIVE CARE; PROTHROMBIN; PROTHROMBIN TIME; SMOKING; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR; WARFARIN;

EID: 0033026582     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008991412759     Document Type: Article

References (33)

1. National Center for Health Statistics. Health, United States, 1996-97 and Injury Chartbook, No. PHS 97-1232. Hyattsville, MD: Department of Health & Human Services Publication, 1997.
2. National Hospital Discharge Survey. Vital Health Statistics, Series 13. Hyattsville, MD: Department of Health & Human Services Publication, 1990.
3. Barboriak JJ, Batayias GE, Pintar K, Korns ME. Pathological changes in surgically removed aortocoronary vein grafts. Ann Thorac Surg 1976;21:524-527.
4. Campeau L, Enjalbert M, Lesperance J, et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation. A study 10 years after aortocoronary bypass surgery. N Engl J Med 1984;311:1329-1332.
5. Neitzel GF, Barboriak JJ, Pintar K, Qureshi I. Atherosclerosis in aortocoronary bypass grafts. Morphologic study and risk factor analysis 6 to 12 years after surgery. Arteriosclerosis 1986;594-600.
6. Solymoss BC, Nadeau P, Millette D, Campeau L. Late thrombosis of saphenous vein coronary bypass grafts related to risk factors. Circulation 1988;78(Suppl. I):I140-I143.
7. Poller L, McKernan A, Thomson JM, Elstein M, Hirsch PJ, Jones JB. Fixed minidose warfarin: A new approach to prophylaxis against venous thrombosis after major surgery. Br Med J 1987;295:1309-1312.
8. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.
9. Gohlke H, Gohlke-Barwolf C, Sturzenhofecker P, et al. Improved graft patency with anticoagulant therapy after aortocoronary bypass surgery; a prospective, randomized study. Circulation 1981;64(Suppl. 2):1122-1127.
10. van der Meer J, Hillege HL, Dunselman JM, et al. Oral anticoagulation in the prevention of one-year vein graft occlusion after aortocoronary bypass surgery: Optimal therapeutic range and practical limitations. Thromb Haemost 1994;72:676-681.
11. Turpie AGG, Gunstensen J, Hirsh J, Nelson H, Gent M. Randomised comparison of two intensities of oral anticoagulant therapy after tissue heart valve replacement. Lancet 1988;1:1242-1245.
12. Dale C, Gallus AS, Wycherley A, Langlois S, Howie D. Prevention of venous thrombosis with minidose warfarin after joint replacement. Br Med J 1991;303:224.
13. Fordyce MJP, Baker AS, Staddon GE. Efficacy of fixed minidose warfarin prophylaxis in total hip replacement. Br Med J 1991;303:219-220.
14. Dalaker K, Smith P, Arnesen H, Prydz H. Factor VII-phospholipid complex in male survivors of acute myocardial infarction. Acta Med Scand 1987;222:111-116.
15. Broadhurst P, Kelleher C, Hughes L, Imeson J, Raferty E. Fibrinogen, factor VII clotting activity and coronary artery disease severity. Atherosclerosis 1990;85:169-173.
16. Poller L, MacCallum PK, Thomson JM, Kerns W. Reduction of factor VII coagulant activity (VIIC), a risk factor for ischaemic heart disease, by fixed dose warfarin: A double blind crossover study. Br Heart J 1990;63:231-233.
17. Meade TO, Mellows S, Brozovic M, et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986;2:533-537.
18. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor; a meta-analysis and review of the literature. Ann Intern Med 1993;118:963-965.
19. Heinrich J, Balleisen L, Schulte H, Assmann G, van de Loo J. Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men. Arterioscler Thromb 1994;14:54-59.
20. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo, JCW. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 1995;332:635-641.
21. Brännström M, Jansson J-H, Boman K, Nilsson TK. Endothelial haemostatic factors may be associated with mortality in patients on long-term anticoagulant treatment. Thromb Haemost 1995;74:612-615.
22. Miller GJ, Bauer KA, Cooper JA, Rosenberg RD. Activation of the coagulant pathway in cigarette smokers. Thromb Haemost 1998;79:549-553.
23. Feinberg WM, Cornell ES, Nightingale SD, et al. Relationship between prothrombin activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke 1997;28:1101-1106.
24. Mammen EF, Koets MH, Washington BC, et al. Hemostasis changes during cardiopulmonary bypass surgery. Semin Thromb Hemost 1985;11:281-292.
25. Merlini PA, Bauer KA, Oltrona L, et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation 1994;90:61-68.
26. Tripodi A, Cattaneo M, Molteni A, Cesana BM, Mannucci PM. Changes of prothrombin fragment 1 + 2 (F 1 + 2) as a function of increasing intensity of oral anticoagulation. Considerations on the suitability of F 1 + 2 to monitor oral anticoagulant treatment. Thromb Haemost 1998;79:571-573.
27. Jansson J-H, Oloffson BO, Nilsson TK. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: A seven year follow-up. Circulation 1993;88:2030-2034.
28. Lowe GDO, Rumley A, Balendra R, Lee AJ, Tunstall-Pedoe HD. Blood rheology and haemostasis in survivors of premature myocardial infarction: A case-control study. Thromb Haemost 1993;69:796.
29. Smith PB, Lee AJ, Rumley A, Fowkes FGR, Lowe GDO. Tissue plasminogen activator, plasminogen activator inhibitor and risk of peripheral arterial disease. Atherosclerosis 1995;115:35-43.
30. Hamsten A, Paire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987;2:3-8.
31. Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997; 350:389-396.
32. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Adjusted-dose warfarin versus low-intensity, fixed dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 1996;348:633-638.
33. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: Randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk. Lancet 1998;351:233-241.